Based on the results of the RESPECT trial - the largest and longest follow-up study that randomized patients with cryptogenic stroke to PFO device closure versus medical therapy- the FDA approved the Amplatzer PFO occluder on October 28, 2016.
The RESPECT trial showed that the incidence of strokes was almost halved in patients who had their PFO closed compared with those who received medical therapy alone
NEW! For information about non-invasive testing for PFO
A Patent Foramen Ovale (PFO) is a type of hole between the upper chambers of the heart. 10-30% of adults have a PFO.
While a PFO usually does not cause problems, in some it may be a risk factor for stroke.
In certain cases, it may be advisable to close a PFO. Dr. Barry Love is an expert in the closure of these heart defects using minimally-invasive catheter techniques.
This website is designed to answer many of your questions about PFO and PFO closure. However, please remember that no amount of information from the Web or other sources replaces the advice and care of a trusted physician.